CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2018	Jun. 30, 2018	Jun. 30, 2017
Current Assets:
Cash and cash equivalents	$ 492,860,000	$ 612,057,000	$ 43,394,000
Marketable securities	4,941,000	26,745,000	111,508,000
Accounts receivable, net of allowances of $0, $0 and $9 at December 31, 2018, June 30, 2018, and 2017, respectively	0	46,000	489,000
Inventory	0	0	580,000
Prepaid expenses	5,354,000	3,803,000	891,000
Other current assets	1,348,000	5,729,000	436,000
Total current assets	504,503,000	648,380,000	157,298,000
Property and equipment, net of accumulated depreciation of $4,316, $30,858 and $29,561 at December 31, 2018, June 30, 2018 and 2017, respectively	23,469,000	15,733,000	5,245,000
Other long-term assets	68,000	60,000	30,000
Total Assets	528,040,000	664,173,000	162,573,000
Current Liabilities:
Accounts payable and accrued expenses	31,722,000	31,664,000	31,367,000
Liability related to sale of future royalties - current	0	3,009,000	0
Warrant liabilities	0	8,973,000	90,706,000
Deferred revenues	0	94,000	171,000
Total current liabilities	31,722,000	43,740,000	122,244,000
Convertible senior notes, net	7,055,000	19,763,000	98,084,000
Liability related to sale of future royalties - non-current	221,295,000	198,998,000	0
Other long-term liabilities	2,119,000	1,986,000	1,709,000
Total Liabilities	262,191,000	264,487,000	222,037,000
Commitments and Contingencies (Note 15)
Stockholders' Equity (Deficit):
Convertible preferred stock, $0.1 par value; authorized 10,000,000 shares; no shares issued and outstanding at December 31, 2018, June 30, 2018 and 1,000,000 shares issued and outstanding at June 30, 2017	0	0	10,000
Common stock, $0.1 par value; authorized 250,000,000 shares; issued 190,445,795 shares and outstanding 190,411,070 shares at December 31, 2018; issued 186,801,159 shares and outstanding 186,766,434 shares at June 30, 2018; shares issued 110,344,643 shares and outstanding 110,309,918 shares at June 30, 2017	1,905,000	1,868,000	1,103,000
Capital contributed in excess of par	1,219,237,000	1,194,998,000	462,666,000
Treasury stock, at cost: 34,725 shares at December 31, 2018, June 30, 2018 and 2017	(824,000)	(458,000)	(458,000)
Accumulated deficit	(953,216,000)	(795,548,000)	(521,711,000)
Accumulated other comprehensive loss	(351,000)	(353,000)	(303,000)
Total Immunomedics, Inc. stockholders' equity (deficit)	266,751,000	400,507,000	(58,693,000)
Noncontrolling interest in subsidiary	(902,000)	(821,000)	(771,000)
Total stockholders' equity (deficit)	265,849,000	399,686,000	(59,464,000)
Total Liabilities and Stockholders' Equity	$ 528,040,000	$ 664,173,000	$ 162,573,000